1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The cancer immunotherapy market is transforming global oncology by advancing innovative therapies that modify the immune system to target malignancies. This evolution is reshaping treatment standards, driving new care pathways, and influencing strategic decision-making for healthcare stakeholders worldwide.
Market Snapshot: Cancer Immunotherapy Market Overview
The Cancer Immunotherapy Market grew from USD 77.39 billion in 2024 to USD 81.74 billion in 2025. It is expected to continue growing at a CAGR of 5.57%, reaching USD 107.17 billion by 2030.
Scope & Segmentation
- Therapy Types: Cancer vaccines, CAR-T therapies, CTLA-4 inhibitors, oncolytic virus therapies, PD-1 inhibitors, and PD-L1 inhibitors.
- Mechanisms of Action: Adoptive cell transfer, checkpoint inhibition, cytokine therapy, oncolytic virus modalities, vaccine therapies.
- Lines of Therapy: First-line, second-line, third-line, and fourth-line and beyond interventions for diverse oncology protocols.
- Routes of Administration: Intratumoral, intravenous, and subcutaneous options designed for clinical and outpatient settings.
- Indications: Hematologic malignancies (leukemia, lymphoma, multiple myeloma) and a spectrum of solid tumors (breast, colorectal, lung, melanoma).
- End Users: Hospitals, research institutes, and specialty clinics delivering advanced immunotherapeutic care.
- Covered Regions: Americas (including key US states and major countries in the region), Europe, Middle East & Africa (featuring leading and emerging healthcare markets), Asia-Pacific (spanning high-growth economies and biotech hubs).
- Company Analysis: Focused on industry leaders such as Merck & Co., Bristol-Myers Squibb, F. Hoffmann-La Roche, Novartis, AstraZeneca, Pfizer, Johnson & Johnson, Amgen, Sanofi, and Gilead Sciences.
Cancer Immunotherapy: Key Takeaways for Decision-Makers
- Immunotherapy has shifted from experimental to standard practice, with new modalities integrated into mainstream treatment approaches across multiple cancer types.
- Strategic collaborations between biopharma companies and innovative biotech firms are accelerating early-stage discovery and expanding pipeline diversity.
- Personalized medicine, supported by genomic and proteomic profiling, optimizes therapy selection and patient outcomes.
- Regulatory and reimbursement landscapes remain complex, as stakeholders seek to balance clinical benefits, access, and cost sustainability.
- Digital health and remote monitoring are enhancing patient management, trial efficiency, and post-market vigilance.
Tariff Impact on Cancer Immunotherapy Supply Chain
Recent US tariffs on raw materials, manufacturing equipment, and biologics components are impacting cost structures and supply chain strategies throughout the cancer immunotherapy ecosystem. Manufacturers have begun evaluating alternative sourcing, localizing production partnerships, and intensifying process optimization to preserve operational resilience amid evolving trade scenarios. Regulatory flexibility is mitigating potential disruptions, enabling accelerated review of manufacturing and protocol changes tied to tariff adjustments.
Methodology & Data Sources
This analysis integrates primary interviews with key opinion leaders—including oncologists, immunologists, and bioprocessing experts—alongside in-depth secondary research covering scientific literature, regulatory filings, and strategic industry disclosures. Patent reviews and technology assessments map emerging platforms. Triangulation of market intelligence, trial results, and expert insights underpins the validity of findings. Rigorous ethical standards and transparent quality checks ensure data integrity.
Cancer Immunotherapy Market: Why This Report Matters
- Enables executives to benchmark strategic priorities against detailed market segmentation and technology adoption pathways.
- Provides actionable intelligence to optimize investment, pipeline management, and cross-functional partnerships within rapidly evolving regulatory and commercial landscapes.
- Illuminates regional market differentiation, ensuring resource allocation and go-to-market strategies reflect nuanced global dynamics.
Conclusion
Cancer immunotherapy is redefining treatment possibilities, propelled by scientific progress, regulatory adaptation, and collaborative partnerships. Stakeholders who leverage actionable insight, embrace agile strategies, and prioritize cross-sector alliances will shape the next wave of oncology innovation.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of single-cell sequencing data to identify novel tumor antigens for personalized immunotherapy
5.2. Advancement in gene editing-enhanced CAR T-cell therapies targeting solid tumor microenvironment
5.3. Emergence of microbiome modulation strategies to improve checkpoint inhibitor response rates
5.4. Adoption of AI-driven predictive biomarkers for early assessment of patient response to immunotherapy
5.5. Development of off-the-shelf allogeneic NK cell therapies with engineered safety switch mechanisms
5.6. Combination approaches leveraging oncolytic viruses and immune checkpoint blockade for resistant cancers
5.2. Advancement in gene editing-enhanced CAR T-cell therapies targeting solid tumor microenvironment
5.3. Emergence of microbiome modulation strategies to improve checkpoint inhibitor response rates
5.4. Adoption of AI-driven predictive biomarkers for early assessment of patient response to immunotherapy
5.5. Development of off-the-shelf allogeneic NK cell therapies with engineered safety switch mechanisms
5.6. Combination approaches leveraging oncolytic viruses and immune checkpoint blockade for resistant cancers
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. Cancer Immunotherapy Market, by Therapy Type
8.1. Introduction
8.2. Cancer Vaccines
8.3. CAR-T Therapy
8.4. CTLA-4 Inhibitors
8.5. Oncolytic Virus Therapy
8.6. PD-1 Inhibitors
8.7. PD-L1 Inhibitors
8.2. Cancer Vaccines
8.3. CAR-T Therapy
8.4. CTLA-4 Inhibitors
8.5. Oncolytic Virus Therapy
8.6. PD-1 Inhibitors
8.7. PD-L1 Inhibitors
9. Cancer Immunotherapy Market, by Mechanism Of Action
9.1. Introduction
9.2. Adoptive Cell Transfer
9.3. Checkpoint Inhibitors
9.4. Cytokine Therapy
9.5. Oncolytic Virus Therapy
9.6. Vaccine Therapy
9.2. Adoptive Cell Transfer
9.3. Checkpoint Inhibitors
9.4. Cytokine Therapy
9.5. Oncolytic Virus Therapy
9.6. Vaccine Therapy
10. Cancer Immunotherapy Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Fourth Line And Beyond
10.4. Second Line
10.5. Third Line
10.2. First Line
10.3. Fourth Line And Beyond
10.4. Second Line
10.5. Third Line
11. Cancer Immunotherapy Market, by Route Of Administration
11.1. Introduction
11.2. Intratumoral
11.3. Intravenous
11.4. Subcutaneous
11.2. Intratumoral
11.3. Intravenous
11.4. Subcutaneous
12. Cancer Immunotherapy Market, by Indication
12.1. Introduction
12.2. Hematologic Malignancies
12.2.1. Leukemia
12.2.2. Lymphoma
12.2.3. Multiple Myeloma
12.3. Solid Tumors
12.3.1. Breast Cancer
12.3.2. Colorectal Cancer
12.3.3. Lung Cancer
12.3.4. Melanoma
12.2. Hematologic Malignancies
12.2.1. Leukemia
12.2.2. Lymphoma
12.2.3. Multiple Myeloma
12.3. Solid Tumors
12.3.1. Breast Cancer
12.3.2. Colorectal Cancer
12.3.3. Lung Cancer
12.3.4. Melanoma
13. Cancer Immunotherapy Market, by End User
13.1. Introduction
13.2. Hospitals
13.3. Research Institutes
13.4. Specialty Clinics
13.2. Hospitals
13.3. Research Institutes
13.4. Specialty Clinics
14. Americas Cancer Immunotherapy Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Cancer Immunotherapy Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Cancer Immunotherapy Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Bristol-Myers Squibb Company
17.3.3. F. Hoffmann-La Roche Ltd
17.3.4. Novartis AG
17.3.5. AstraZeneca PLC
17.3.6. Pfizer Inc.
17.3.7. Johnson & Johnson
17.3.8. Amgen Inc.
17.3.9. Sanofi S.A.
17.3.10. Gilead Sciences, Inc.
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Bristol-Myers Squibb Company
17.3.3. F. Hoffmann-La Roche Ltd
17.3.4. Novartis AG
17.3.5. AstraZeneca PLC
17.3.6. Pfizer Inc.
17.3.7. Johnson & Johnson
17.3.8. Amgen Inc.
17.3.9. Sanofi S.A.
17.3.10. Gilead Sciences, Inc.
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. CANCER IMMUNOTHERAPY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. CANCER IMMUNOTHERAPY MARKET: RESEARCHAI
FIGURE 28. CANCER IMMUNOTHERAPY MARKET: RESEARCHSTATISTICS
FIGURE 29. CANCER IMMUNOTHERAPY MARKET: RESEARCHCONTACTS
FIGURE 30. CANCER IMMUNOTHERAPY MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. CANCER IMMUNOTHERAPY MARKET: RESEARCHAI
FIGURE 28. CANCER IMMUNOTHERAPY MARKET: RESEARCHSTATISTICS
FIGURE 29. CANCER IMMUNOTHERAPY MARKET: RESEARCHCONTACTS
FIGURE 30. CANCER IMMUNOTHERAPY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CANCER IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 121. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 122. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 123. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 124. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 125. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 126. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 127. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 132. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 133. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 134. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 135. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 138. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 139. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 142. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 143. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 148. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 149. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 220. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 221. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 222. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 223. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 224. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 225. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 230. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 231. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 232. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 233. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 236. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 237. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 238. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 239. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 240. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 241. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 246. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 247. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 268. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 269. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 270. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 271. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 272. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 273. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 278. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 279. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 280. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 281. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 284. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 285. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 286. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 287. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 288. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 289. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 294. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 295. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 296. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 297. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 316. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 318. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 320. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 322. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 324. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 326. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MI
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 121. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 122. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 123. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 124. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 125. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 126. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 127. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 132. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 133. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 134. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 135. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 138. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 139. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 142. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 143. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 148. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 149. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 220. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 221. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 222. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 223. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 224. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 225. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 230. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 231. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 232. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 233. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 236. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 237. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 238. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 239. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 240. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 241. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 246. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 247. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 268. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 269. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 270. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 271. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 272. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 273. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 278. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 279. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 280. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 281. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 284. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 285. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 286. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 287. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 288. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 289. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 294. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 295. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 296. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 297. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 316. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 318. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 320. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 322. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 324. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 326. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MI
Samples
LOADING...
Companies Mentioned
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Novartis AG
- AstraZeneca PLC
- Pfizer Inc.
- Johnson & Johnson
- Amgen Inc.
- Sanofi S.A.
- Gilead Sciences, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | August 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 81.74 Billion |
| Forecasted Market Value ( USD | $ 107.17 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
